Pharmaceuticals Biotechnology and Life Sciences
featured
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
» Read MoreMore
-
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
-
ALLEGAN, Mich.-- Perrigo Co.' s fiscal second quarter earnings climbed 6 percent in a performance that topped Wall Street expectations, as revenue gains from acquisitions and the over-the-counter drugmaker's consumer health care segment countered rising expenses.
-
Pfizer's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook.
-
Feb 1- Merck& Co Inc's quarterly results beat estimates, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company forecast 2013 profit at the low end of expectations. The No. 2 U.S. drugmaker said it earned $1.4 billion, or 46 cents per share, in the fourth quarter.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
-
*Quarterly sales $11.74 bln, vs view $11.48 bln. Feb 1- Merck& Co Inc's quarterly results beat estimates, but the drugmaker issued a cautious 2013 profit forecast and said it will delay seeking approval for a high-profile osteoporosis drug, sending its shares down 3 percent.
-
CHICAGO, Feb 1- After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. "In my own personal view, I will consider this to be a landmark or a watershed," said Peggy Johnston, senior program officer at the Bill& Melinda Gates Foundation in Seattle.
-
WASHINGTON-- Shares of Halozyme Therapeutics tumbled 8 percent Thursday after a Wall Street analyst downgraded the specialty drugmaker, saying that European regulators may not approve a key cancer drug this year.
-
Jan 31- Ben Venue Laboratories Inc., a unit of German drug company Boehringer Ingelheim, may not freely make or distribute drugs from its facility in Bedford, Ohio, until U.S. regulators have determined it is in compliance with good manufacturing standards. Ben Venue has repeatedly violated good manufacturing practices, the FDA said in a statement.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
-
BRUSSELS, Jan 31- EU antitrust regulators stepped up their fight against companies blocking the market entry of cheaper generic medicines, with charges against Johnson& Johnson and Novartis over a pay-for-delay deal in the Netherlands.
-
BRUSSELS, Jan 31- EU antitrust regulators charged pharmaceutical firms Johnson& Johnson and Novartis on Thursday over the delay of a generic competitor for painkiller fentanyl in the Dutch market.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said the drugmaker faced a tough year, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continued to erode business.
-
*Q4 sales $7.28 billion vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss warned on Thursday the drugmaker faced a tough year in 2013, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continue to erode business.
-
NEW YORK, Jan 30- Sarepta Therapeutics Inc became the second company in as many days see its shares plunge as a result of a Twitter hoax on Wednesday after a user posed as an influential short-seller and alleged improprieties at the biopharmaceutical company.
-
*Warner Chilcott, Valeant Pharmaceuticals among interested parties-sources. NEW YORK, Jan 30- Endo Health Solutions Inc has held talks in recent weeks with drugmakers potentially interested in buying the maker of pain relief medication, people familiar with the matter said on Wednesday.
-
NEW YORK-- Shares of Isis Pharmaceuticals Inc. soared Wednesday on news that the U.S. Food and Drug Administration approved its new drug application for its Kynamro cholesterol drug. Carlsbad, Calif.- based Isis has a deal with Genzyme, a unit of French drugmaker Sanofi SA, to market the drug if it is approved.
-
Jan 30- AbbVie, the pharmaceuticals business spun off earlier this month by Abbott Laboratories, forecast 2013 earnings in line with Wall Street forecasts. AbbVie said it expects net earnings this year of $2.66 to $2.76 per share. Abbott last week said global sales of branded drugs that now belong to AbbVie rose 7.4 percent to $5.14 billion.